Brief Summary
The purpose of this study is to compare pembrolizumab (MK-3475) in combination with sacituzumab govitecan with pembrolizumab alone with respect to progression-free survival (PFS) and overall survival (OS) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as assessed by blinded independent central review (BICR) among adults with metastatic non-small cell lung cancera disease where abnormal cells split without control and spread to other nearby body tissue and/or organs (NSCLC) with programmed cell death ligand 1 (PD-L1) tumor proportion score (TPS) ≥50%).
Intervention / Treatment
- Biological: Sacituzumab Govitecan
- Biological: Pembrolizumab
Inclusion Criteria:
The main inclusion criteria include but are not limited to the following:
- Has a histologically or cytologically confirmed diagnosisthe process of identifying a disease based on signs and symptoms, patient history and medical test results of metastatic non-small cell lung cancer (NSCLC)
- Has confirmation that epidermal growth factor receptor (EGFR), anaplastica term used to describe abnormal cancer cells that grow uncontrollably in the body and have little or no resemblence to regular cells lymphomacancers of the lymphatic system kinase 1 (ALK-1), or ROS proto-oncogenea type of gene that normally regulates cell growth and division, but when mutated can cause uncontrollable cell growth and may lead to cancer 1 (ROS-1)-directed therapy is not indicated as primary therapy
- Has provided tumor tissuea group of cells that work together to perform a function that demonstrates PD-L1 tumor proportion score (TPS) ≥50% of tumor cellsthe basic structural and functional unit of all living things as assessed by immunohistochemistry (IHC) at a central laboratory
- Has a life expectancy of at least 3 months